<DOC>
	<DOCNO>NCT02424513</DOCNO>
	<brief_summary>This prospective , multicenter , open-label , non-randomized study evaluate ability [ 89 ] Zr-Df-IAb2M detect local , regional metastatic prostate cancer confirm pathology .</brief_summary>
	<brief_title>A Study Positron Emission Tomography ( PET ) With 89Zr-Df-IAb2M Patients With High-risk Prostate Cancer</brief_title>
	<detailed_description>IAB2M approximately 80 kDA molecular weight antibody fragment ( `` Minibody '' ) chelate Desferroxamine radiolabeled [ 89 ] Zr . [ 89Zr ] -Df-IAB2M target extracellular domain Prostate Membrane Specific Antigen ( PSMA ) express primary metastatic prostate cancer lesion . This phase 2 , prospective , multi-center , open-label , non-randomized study evaluate ability [ 89 ] Zr-Df-IAb2M detect local , regional metastatic prostate cancer confirm pathology patient biopsy-proven prostate cancer think candidate radical prostatectomy pelvic lymph node dissection high-risk pelvic lymph node metastasis . These patient may identify lymphadenopathy conventional imaging consider eligible still judge candidate radical prostatectomy lymph node dissection .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Histological diagnosis prostate adenocarcinoma . 2 . Patients consider candidate radical prostatectomy pelvic lymph node dissection . These patient may may identify nodal metastasis conventional imaging would still candidate radical prostatectomy pelvic lymph node dissection . 3 . Patients , highrisk pelvic lymph node metastasis define lymph node involvement risk great equal 20 % use Briganti nomogram . 4 . Age â‰¥ 18 year . 5 . Ability understand willingness sign IRB approve consent form 6 . For men childproducing potential , use effective contraceptive method study . 1 . Treatment plan treatment radiation therapy , surgery , chemotherapy , investigational therapy time conventional imaging , [ 89 ] ZrDfIAB2M PET/CT surgical resection biopsy procedure use study evaluation . 2 . Unwillingness inability comply procedure require protocol . 3 . Other cancer might potentially interfere read interpretation [ 89 ] ZrDfIAB2M PET/CT scan . 4 . Patients currently receive investigational agent . 5 . Patients currently receive androgen deprivation therapy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>